approvals: T2D (Mounjaro, 2022), obesity (Zepbound, 2023), and obstructive sleep apnea with obesity (Zepbound, 2024) Ongoing Innovations in GLP-1s Landscape The obesity pipeline from phase 1 to market now includes 173 drugs, with GLP-1 and combination therapies accounting for majority of trials
However, severe vomiting that prevents you from keeping down food or liquids for more than a few hours requires immediate medical attention to rule out other conditions
Patients know their health is never compromised for speed
He understands how body composition, skin quality, and metabolic health intersect and how weight changes can impact your appearance, confidence, and surgical options
Do not start this medication if you have been diagnosed with coronary artery disease
The market size will continue expanding